“This certainly doesn't look like the stock of a company on the verge of any significant breakthrough.”
Not complicated. If’s called the “Missling Discount”.
No serious biotech institutional investors or top-tier analysts believe anything this Missling guy says and they have no faith in his ability to execute. Think about who participates on the quarterly calls: A third-tier security analyst, a stock newsletter editor, and a fake biotech analyst.